Alzinova AB is a privately held Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. A platform technology based on the AβCC™ peptides provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.Read more »
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy, and non-toxic mimetic amyloid-β as replacement therapy. The unique properties of the AβCC™ peptide platform technology has also enabled the development of a monoclonal antibody with 100% specificity for the disease-driving oligomers.
Founded in 1984, Alzheimer’s Disease International (ADI) is the international federation of 79 different Alzheimer… Read more »
The October issue (no. 10, 2013) of the Swedish magazine ”Kemivärlden Biotech” profiles Alzinova as one… Read more »
Alzinova representatives will attend the 19th annual BIO-Europe® Conference, which is Europe’s largest partnering venue for… Read more »